Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics


Mersana Therapeutics, Inc. (MRSN)

Today's Latest Price: $20.79 USD

0.46 (2.26%)

Updated Aug 5 11:34am

Add MRSN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

MRSN Stock Summary

  • MRSN's price/sales ratio is 1,090.48; that's higher than the P/S ratio of 99.39% of US stocks.
  • As for revenue growth, note that MRSN's revenue has grown -97.74% over the past 12 months; that beats the revenue growth of merely 0.66% of US companies in our set.
  • The volatility of Mersana Therapeutics Inc's share price is greater than that of 96.72% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are CBMG, INO, GERN, SCYX, and ADAP.
  • Visit MRSN's SEC page to see the company's official filings. To visit the company's web site, go to www.mersana.com.
MRSN Daily Price Range
MRSN 52-Week Price Range

MRSN Stock Price Chart Technical Analysis Charts


MRSN Price/Volume Stats

Current price $20.79 52-week high $24.97
Prev. close $20.33 52-week low $1.32
Day low $20.35 Volume 143,764
Day high $21.10 Avg. volume 1,296,939
50-day MA $21.22 Dividend yield N/A
200-day MA $9.99 Market Cap 1.39B

Mersana Therapeutics, Inc. (MRSN) Company Bio


Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.





MRSN Latest News Stream


Event/Time News Detail
Loading, please wait...

MRSN Latest Social Stream


Loading social stream, please wait...

View Full MRSN Social Stream

Latest MRSN News From Around the Web

Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the company’s proprietary approach to precisely upregulate protein expression using TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotides (ASOs).

Yahoo | July 9, 2020

Here is What Hedge Funds Think About Stoke Therapeutics, Inc. (STOK)

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

Yahoo | July 8, 2020

The Zacks Analyst Blog Highlights: Everbridge, Baozun, Zoom Video Communications, Mersana Therapeutics and Okta

The Zacks Analyst Blog Highlights: Everbridge, Baozun, Zoom Video Communications, Mersana Therapeutics and Okta

Yahoo | July 1, 2020

Nasdaq's Rally to Continue in 2H20: 5 Momentum Stocks to Buy

Here we pick five Nasdaq-listed momentum stocks that are well-poised to grow on solid prospects in the remainder of 2020.

Yahoo | June 30, 2020

Mersana's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

Yahoo | June 26, 2020

Read More 'MRSN' Stories Here

MRSN Price Returns

1-mo -6.39%
3-mo 107.49%
6-mo 215.48%
1-year 545.65%
3-year 38.51%
5-year N/A
YTD 262.83%
2019 40.44%
2018 -75.17%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8547 seconds.